AAP
MGX icon

Arax Advisory Partners’s Metagenomi Therapeutics MGX Stock Holding History

Arax Advisory Partners’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11
Closed -$18 – 4399
2025
Q4 		$18 Sell
11
-19
-63% -$41 ﹤0.01% 4029
2025
Q3 		$71 Buy
+30
New +$61 ﹤0.01% 3521

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arax Advisory Partners's MGX Position: Q1 2026 in Review

Arax Advisory Partners sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 11 shares — an estimated $18 sold.

Arax Advisory Partners first reported a position in MGX in Q3 2025 and held it in 2 quarters. The position peaked at $71 in Q3 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Arax Advisory Partners reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 11 Metagenomi Therapeutics shares in Q1 2026, an estimated $18.
  • Arax Advisory Partners first reported a position in Metagenomi Therapeutics in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Metagenomi Therapeutics position peaked at $71 in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.